Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, SUTRO BIOPHARMA, INC. reported revenue of $102M, up 65.2% year over year. Operating margin was -154.5% and net margin -186.5%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from STRO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $102M | -154.5% | -186.5% |
| FY2024 | $62M | -384.3% | -366.6% |
| FY2023 | $154M | -58.1% | -69.5% |
| FY2022 | $68M | -190.3% | -175.9% |
| FY2021 | $62M | -159.2% | -170.6% |
How does STRO compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.